Connolly SJ.  et al. Newly identified events in the RE-LY trial.  N Engl J Med.  2010;363:1875-6.

PRADAXAa  US Prescribing Information, 2014.

Pradaxa?  European Summary of Product Characteristics, 2014.

Graham J.  et al.  Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for non-valvular atrial fibrillation. Circulation. 2014. doi: 10.1161/CIRCULATIONAHA.114.012061 Published online  October 30, 2014.

Boehringer Ingelheim data on file.

Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.  Clin Pharmacokinet.  2008;47(5):285–95.

Di Nisio M.  et al. Direct thrombin inhibitors.  N Engl J Med.  2005;353:1028-40.

Stangier J.  et al. Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement.  J Clin Pharmacol.  2005;45:555-63.

[*] 在美国，肌酐清除率介于30-15 ml/min之间患者的适用剂量为75mg每日两次[5]。对于这一适应症，75mg每日两次的剂量尚未在欧洲以及中国获批[6]。

消息来源: 勃林格殷格翰